ViridianCares™

ViridianCares is a support program to help your patients start and stay on treatment

ViridianCares supports your practice and your patients by providing access and reimbursement support, including helping with enrollment, insurance processes, affordability programs, and treatment coordination to help your patients start and stay on treatment.

Enrollment Steps

Enrolling your patient is a critical first step. There are 2 ways to complete the enrollment form:

1. Complete form, ensure patient reviews and signs, and then fax all 4 pages to 1-833-726-5151.

Patient Enrollment Form for Lumvoa™ (veligrotug-vvze)

OR

2. Complete the EZ Enroll enrollment form electronically

EZ Enroll Patient Enrollment Form

ViridianCares Co-pay Program

Eligible Lumvoa patients may pay as little as $0 in out-of-pocket costs*

The ViridianCares Co-Pay Program offers co-pay assistance for eligible patients. Commercially insured patients may pay as little as $0* for medication and infusion-related expenses. Terms and conditions apply.

For financial assistance programs, the process begins when your office enrolls a patient by submitting the appropriate enrollment form. Once an enrollment form is submitted, ViridianCares will work with your patient to further determine eligibility and benefits.

*Patients must be enrolled in ViridianCares and meet all eligibility requirements. Terms and conditions will apply.

See terms and conditions.

ViridianCares helps your patients start and stay on treatment

Dedicated patient access liaisons (PALs)
Tools to help facilitate insurance approval
Financial assistance programs for eligible patients
Patient education and treatment support

For questions about enrollment in ViridianCares, call 1-866-VCARES1,

Monday through Friday, 8 AM to 8 PM ET

Patient Access Liaisons

Once a patient is enrolled, a dedicated PAL serves as a single point of contact for your practice, your patient, and infusion centers.

Your PAL is available to provide support for your patients. PALs can help navigate a wide array of issues, such as patient onboarding, insurance approvals, prior authorizations, and treatment logistics—all with the aim of helping you start and keep patients on therapy.

Find information and infusion resources for your practice

Indication: Lumvoa is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

Important Safety Information

Infusion Reactions: Lumvoa may cause infusion reactions. Infusion reactions have been reported in approximately 9% of patients treated with Lumvoa. Signs and symptoms of infusion-related reactions include transient increases in blood pressure, fever, chills, headache, and fatigue. Infusion reactions may occur during or soon after an infusion. Reported infusion reactions are usually mild or moderate in severity and can usually be successfully managed with corticosteroids, antihistamines, and antipyretics. In patients who experience an infusion reaction, consideration should be given to standard premedication and/or administering infusions at a slower infusion rate.

Inflammatory Bowel Disease: Lumvoa may cause an exacerbation of inflammatory bowel disease (IBD). IBD has been reported in some patients receiving insulin-like growth factor-1 receptor inhibitors without a prior diagnosis of IBD. Monitor patients for signs and symptoms of IBD, including patients without a history of IBD. If IBD is suspected, discontinue use of Lumvoa.

Hyperglycemia: Hyperglycemia or increased blood glucose may occur in patients treated with Lumvoa. In clinical trials, 12% of patients, of whom one-half had preexisting diabetes or impaired glucose tolerance, experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with Lumvoa. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving Lumvoa. Continued monitoring after treatment is recommended for patients who experience hyperglycemia while on Lumvoa.

Hearing Impairment Including Hearing Loss: Lumvoa may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients’ hearing before, during, and after treatment with Lumvoa and consider the benefit-risk of treatment with patients.

Most Common Adverse Events: Most common adverse reactions (incidence of 5% or more) are muscle spasms, headache, hearing impairment, hyperglycemia, fatigue, diarrhea, ear discomfort, infusion-related reaction, nausea, nasopharyngitis, blood creatine phosphokinase increased, dry skin, and hypertension.

Females of Reproductive Potential: Appropriate forms of contraception should be implemented prior to initiation, during treatment, and for 6 months following the last dose of Lumvoa.

Lumvoa (500 mg) is an injection for infusion.

Please see accompanying Full Prescribing Information.